Brainstorm Cell Therapeutics Inc. - Common Stock (NQ: BCLI )
1.860
+0.060
(+3.33%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
All News about Brainstorm Cell Therapeutics Inc. - Common Stock
![](https://cdn.benzinga.com/files/images/story/2012/biotech_6.jpg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/ep_us_feature_image_1694.jpeg)
![](https://cdn.benzinga.com/files/images/story/2012/lab-5740505_1920_10.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/earnings_image_6576.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/ep_us_feature_image_3053.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/earnings_image_3094.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/earnings_image_3081.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/biotech4_3.jpg)
Via Benzinga
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_167.jpeg)
Alzheimer’s Disease Expected to Triple by 2050 While the Development Process for Potential Drug Candidates Increases
January 05, 2022
Topics
Death
Exposures
Death
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/mid-day_movers_image_78.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_350.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/premkt_movers_511.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_2636.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png)
68 Biggest Movers From Wednesday
November 26, 2021
Via Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_256.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/premkt_movers_379.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/earnings_scheduled_1848.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/laboratory-3827745_1920_38_0_4.jpg)
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
April 24, 2021
Via Benzinga
Exposures
Product Safety
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.